923009-49-8

Basic information

• Product Name: 1,3-Piperidinedicarboxylic acid, 3-(cyanomethyl)-, 1-(1,1-dimethylethyl) 3-ethyl ester
• Synonyms: 1,3-Piperidinedicarboxylic acid, 3-(cyanomethyl)-, 1-(1,1-dimethylethyl) 3-ethyl ester;1,3-PIPERIDINEDICARBOXYLIC ACID, 3-(CYANOMETHYL)-, 1-(1,1-DIMETHYLETHYL) 3-ETHYL ESTER(WX618184)
• CAS NO: 923009-49-8
• Molecular Formula: C15H24N2O4
• Molecular Weight: 296.36
• Mol File: 923009-49-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,3-Piperidinedicarboxylic acid, 3-(cyanomethyl)-, 1-(1,1-dimethylethyl) 3-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Piperidinedicarboxylic acid, 3-(cyanomethyl)-, 1-(1,1-dimethylethyl) 3-ethyl ester(923009-49-8)
• EPA Substance Registry System: 1,3-Piperidinedicarboxylic acid, 3-(cyanomethyl)-, 1-(1,1-dimethylethyl) 3-ethyl ester(923009-49-8)

Safety Data

• Hazardous Substances Data: 923009-49-8(Hazardous Substances Data)

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule of the compound.
2. Derivative of piperidinedicarboxylic acid

Explanation

The compound is derived from piperidinedicarboxylic acid, which is a six-membered nitrogen-containing ring structure.
3. Building block in organic synthesis

Explanation

It is used as a starting material or intermediate in the synthesis of more complex organic compounds.
4. Pharmaceutical research and drug development

Explanation

The compound is utilized in the development of new drugs and pharmaceuticals due to its potential medicinal properties.
5. Medicinal properties

Explanation

The compound has properties that make it potentially useful in the treatment or prevention of diseases.
6. Chemical and physical properties

Explanation

The compound possesses a range of properties that make it suitable for various applications in the field of medicinal and pharmaceutical chemistry.
7. Importance in medicinal and pharmaceutical chemistry

Explanation

The compound plays a significant role in the development of new drugs and therapies, contributing to advancements in the field.

Upstream product

• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 
• 590-17-0 cyanomethyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 923009-51-2 C₁₅H₂₆N₂O₃ 

Relevant articles and documents

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the

Design, synthesis, and structure-activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors

The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly2162 and Glu2230, we used ligand- and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety

SPIRO-RING COMPOUND

The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.